Goldman Sachs
QNCX icon

Goldman Sachs’s Quince Therapeutics QNCX Stock Holding History

Goldman Sachs’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80
Closed -$1.63K – 6911
2026
Q1 		$1.63K Sell
80
-1,068
-93% -$214K ﹤0.01% 6421
2025
Q4 		$769K Buy
+1,148
New +$578K ﹤0.01% 5312
2022
Q4 		– Sell
-148
Closed -$39K – 6219
2022
Q3 		$39K Sell
148
-294
-67% -$112K ﹤0.01% 5826
2022
Q2 		$196K Buy
442
+134
+44% +$94.7K ﹤0.01% 5651
2022
Q1 		$381K Sell
308
-308
-50% -$419K ﹤0.01% 5510
2021
Q4 		$1.55M Buy
616
+412
+202% +$2.51M ﹤0.01% 4464
2021
Q3 		$3.74M Buy
204
+81
+66% +$1.29M ﹤0.01% 3600
2021
Q2 		$1.3M Buy
123
+20
+19% +$168K ﹤0.01% 4561
2021
Q1 		$745K Sell
103
-139
-57% -$1M ﹤0.01% 4832
2020
Q4 		$1.35M Buy
242
+52
+27% +$461K ﹤0.01% 4006
2020
Q3 		$1.9M Sell
190
-3
-2% -$27.3K ﹤0.01% 3605
2020
Q2 		$1.79M Buy
+193
New +$1.77M ﹤0.01% 3535
2020
Q1 		– Sell
-39
Closed -$443K – 5501
2019
Q4 		$443K Sell
39
-1
-3% -$6.03K ﹤0.01% 4567
2019
Q3 		$201K Sell
40
-201
-83% -$1.24M ﹤0.01% 4824
2019
Q2 		$2.05M Buy
+241
New +$1.44M ﹤0.01% 3539

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs's QNCX Position: Q2 2026 in Review

Goldman Sachs sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 80 shares — an estimated $1.63K sold.

Goldman Sachs first reported a position in QNCX in Q2 2019 and held it in 15 quarters. The position peaked at $3.74M in Q3 2021. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Goldman Sachs reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 80 Quince Therapeutics shares in Q2 2026, an estimated $1.63K.
  • Goldman Sachs first reported a position in Quince Therapeutics in Q2 2019 and held it in 15 quarters.
  • Goldman Sachs's Quince Therapeutics position peaked at $3.74M in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.